Understanding GLP-1 Peptides: Semaglutide, Tirzepatide & Retatrutide

GLP-1 receptor agonists represent some of the most researched peptides in metabolic science. This article summarises the mechanism of action, receptor biology, and published trial data across the class.

What is GLP-1?

GLP-1 (Glucagon-Like Peptide-1) is a naturally occurring incretin hormone studied for its role in glucose metabolism and appetite signalling (reviewed by Drucker, 2018). GLP-1 receptor agonists are synthetic peptides designed to mimic these receptor interactions.

Key Mechanisms

• Stimulates insulin secretion in a glucose-dependent manner
• Suppresses glucagon release
• Slows gastric emptying
• Modulates appetite signalling through central nervous system pathways
• Studied for cardiovascular and neuroprotective receptor activity (neuroprotection rests mainly on preclinical work; a 2026 meta-analysis of Parkinson's disease trials found no clinical benefit, Stefanou et al., 2026)

The Three Main Compounds

Semaglutide (Single Agonist)

• Mechanism: Pure GLP-1 receptor agonist
• Half-life: ~7 days (approximately one week in the US prescribing information)

Tirzepatide (Dual Agonist)

• Mechanism: GLP-1 + GIP receptor agonist
• Half-life: ~5 days (US prescribing information)

Key characteristics: dual receptor mechanism studied for combined metabolic pathway effects in trial data. Generally shows greater trial endpoint effects than single agonists, for example against semaglutide in the head-to-head SURPASS-2 and SURMOUNT-5 trials. The GIP pathway adds a complementary insulin-secretion mechanism.

Retatrutide (Triple Agonist)

• Mechanism: GLP-1 + GIP + Glucagon receptor agonist
• Half-life: ~6 days (Urva et al., 2022)

Key characteristics: newest and most complex receptor mechanism. The glucagon pathway adds metabolic versatility studied in trial data. Early trial data shows pronounced effects but a less established research base than the other two compounds. Full specifications, published purity results and factory-direct pricing are on the Retatrutide research page.

Comparing the Three

Trial Endpoint Hierarchy (Published Data)

1. Retatrutide: largest mean body-weight reduction of the three in published trials (up to 24.2% at 48 weeks in Phase 2, Jastreboff et al., 2023; 25.0% at 80 weeks in the Phase 3 TRIUMPH-1 trial, Jastreboff et al., 2026)
2. Tirzepatide: substantial trial endpoint effects, well-studied
3. Semaglutide: established trial endpoint data, most established research base

Note: differences in trial endpoint magnitude do not establish superiority for a given research application; applications vary by study design.

Adverse Events Reported in Published Trials

All three compounds show similar adverse event patterns in published trial data:

• Gastrointestinal findings (most common)
• Nausea (especially during dose-escalation phases of trials)
• Reduced appetite signalling
• Injection-site reactions (reported more often with tirzepatide than semaglutide in the SURMOUNT-5 results)

Trial design note: published trials of these compounds use gradual dose-escalation designs, and trials that compared escalation schemes found fewer gastrointestinal side effects with lower starting doses and smaller steps (Frias et al., 2020; Jastreboff et al., 2023).

Dose-Escalation Designs in the Published Literature

Published trials of all three compounds use gradual dose-escalation designs rather than starting at maximum exposure, and report that lower starting doses and smaller escalation steps were associated with better gastrointestinal tolerability in trial cohorts. Specific amounts, schedules and escalation guidance are outside the scope of research-use-only material.

Storage & Handling

Lyophilised (Powder) Form

• Store at -20°C (freezer) for long-term storage
• Stability: 2-3 years when properly stored
• Protect from light

Reconstituted Form

• Store at 2-8°C (refrigerator); do not freeze
• Use within 28-30 days
• Protect from light (amber vials recommended)

Research Considerations by Compound

Semaglutide Research Applications

• Studies requiring the most established published research base
• Single-mechanism receptor studies
• Cost-conscious research designs

Tirzepatide Research Applications

• Dual-mechanism receptor research
• Studies examining the GIP pathway specifically
• Research models where larger trial endpoint effects are of interest

Retatrutide Research Applications

• Triple-mechanism receptor research questions
• Cutting-edge metabolic pathway research
• Studies examining glucagon-pathway receptor activity

Adverse Event Profile Across the Class

All three compounds show comparable adverse event patterns in published research settings:

• Most adverse events reported in trials are dose-dependent and transient
• Lower starting doses and slower escalation were associated with fewer gastrointestinal events in trials that tested this directly
• Gastrointestinal findings were mostly mild to moderate, occurred mainly during dose escalation and subsided over time in trial cohorts (Wilding et al., 2021; Jastreboff et al., 2022)
• Tirzepatide and semaglutide showed broadly similar gastrointestinal event rates when compared directly (SURPASS-2, SURMOUNT-5); retatrutide has not been compared head to head with either

Research model exclusions: published trial protocols typically exclude participants with a history of pancreatitis, or a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (for example SURMOUNT-1 and TRIUMPH-1).

Future of GLP-1 Research

• Oral formulations under development
• Longer-acting variants under investigation
• Combination-therapy trial designs being explored
• Novel receptor targets under investigation

Conclusion

GLP-1 receptor agonists represent a significant area of metabolic research. Semaglutide offers the most established published profile, tirzepatide a dual receptor mechanism, and retatrutide a triple-agonist mechanism still progressing through clinical trials.

Administration guidance is outside the scope of research-use-only material.

References

1. Aronne LJ, et al. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine. PubMed 40353578
2. Drucker DJ. (2018). Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism. PubMed 29617641
3. Frias JP, et al. (2020). Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes, Obesity and Metabolism. PubMed 31984598
4. Frías JP, et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. PubMed 34170647
5. Jastreboff AM, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. PubMed 35658024
6. Jastreboff AM, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. PubMed 37366315
7. Jastreboff AM, et al. (2026). Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine. PubMed 42814954
8. Stefanou MI, et al. (2026). Efficacy and safety of glucagon-like peptide-1 receptor agonists in Parkinson's disease: a systematic review and meta-analysis of randomized placebo-controlled clinical trials. Therapeutic Advances in Neurological Disorders. PubMed 41631108
9. Urva S, et al. (2022). LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. The Lancet. PubMed 36354040
10. Wilding JPH, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. PubMed 33567185